Man Who Had Three Covid Jabs Has High Antibody Levels
"); jQuery("#212 h3").html("

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1593135_1_20210528174914.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1593135-20210528.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1593135-20210528.htm', 'DCS.dcsqry', '' ); } } }); }); });
2021-05-28 HKT 16:50
Professor Ivan Hung speaks to RTHK's Wendy Wong
A Hong Kong man who received three doses of coronavirus vaccine has a very high antibody level against Covid-19, medical experts said on Friday.
However, they added that they can't determine whether or not this positive discovery is down to him receiving a shot of Sinovac on top of his two BioNTech jabs.
The 32-year-old man first had a dose of BioNTech in March. But his second dose was delayed when vaccinations with the German-made jab were temporarily halted due to packaging defects.
When he couldn't get the BioNTech jab as planned, the man decided to go for a Sinovac one instead.
Then, when use of BioNTech resumed in Hong Kong, he took a second dose of this one as well.
Professor Ivan Hung from the University of Hong Kong said antibody levels vary among vaccinated people as their immune systems react differently.
He said although tests showed the man has an antibody level four times higher than average, some people who only receive two shots of BioNTech can also reach that level.
“That could be the result of two doses of BioNTech or it could be the result of three doses of Covid-19 vaccine. Unfortunately, we did not have the antibody level after the second dose, so we cannot draw any conclusion just by looking at the antibody level,” he said.
“If you compare to the highest level of the subjects who received two doses of BioNTech, it is comparable.”
Hung said people who have received two doses of coronavius vaccine, produced by either BioNTech or Sinovac, will have adequate antibodies and they should last for nine months to a year.
He said people do not need a third dose of vaccine, but will probably require a booster jab next year.
ZA Bank Brings Nasdaq Data To Hong Kong, Expanding US Stock Access And Investor Education
ZA Bank and Nasdaq have announced a collaboration aimed at enhancing digital wealth management in Hong Kong and interna... Read more
Hong Kong To Study One‑Stop Infrastructure For Equities, Bonds And Digital Assets
The Hong Kong Monetary Authority’s (HKMA) CMU OmniClear and the Hong Kong Exchange (HKEX) are set to begin a study on... Read more
Hong Kong To Issue First Stablecoin Licenses In March, Expand Crypto Regulation
Hong Kong will issue its first licenses for fiat-referenced stablecoin issuers in March and introduce new legislation l... Read more
MSIG Joins US$6B IFC Credit Insurance Facility To Boost Emerging Market Lending
MSIG USA and Mitsui Sumitomo Insurance (MSI Japan), together referred to as MSIG, have joined a new insurance-ba... Read more
Why The $2 Trillion Stablecoin Prediction Is Too Low
McKinsey estimates the stablecoin market will hit $2 trillion by 2028. But according to Sam Lin, COO of dtcpay, even th... Read more
RedotPay Eyes US IPO With Potential US$1 Billion Raise
RedotPay is reportedly exploring an IPO in the US that could raise more than US$1 billion, according to people famili... Read more